Pictured: Co-founder Jonathan Zamir
NeuBio’s diagnostic blood tests are highly accurate, minimally invasive, and widely accessible alternatives to costly, subjective, and inaccurate imaging tools. Its products are protected by an IP portfolio of 145 novel biomarkers with the highest accuracy and reproducibility ever documented across Alzheimer’s, Parkinson’s, and ALS.
Hear from NeuBio about their mission and what’s next on the horizon.
Jonathan Zamir, Stern M.B.A. ‘04
Marley Bankoff
Daniel Davis
Molly Scofield
John Ballatine
Andrew Creighton
